At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Emixustatdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
In Brief
A Phase 2 clinical trial evaluating Emixustat for Stargardt Disease and Macular Atrophy. Completed, enrolled 23 participants across 1 site.
Detailed Summary
This is a pharmacodynamics study of emixustat hydrochloride in subjects with macular atrophy secondary to Stargardt disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStargardt Disease, Macular Atrophy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJan 2017
First PostedJan 2017
Primary CompletionNov 2017
Study CompletionDec 2017
TodayJul 2026
First PostedJan 26, 2017
Enrollment StartJan 1, 2017
Primary CompletionNov 1, 2017
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.4 years ago
Interventions
Emixustatdrug
Once daily, tablet for oral administration